Abdelmalik Slassi

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.

NPS Pharmaceuticals, Inc. developed drugs for bone and mineral disorders. It also developed Natpara for the treatment of adult hypoparathyroidism. The company was founded by Hunter Jackson and Thomas N. Parks on October 22, 1986 and is headquartered in Bedminster, NJ.

Cascade Therapeutics, Inc. is an American company that engages in the research of biological products. The private company is based in Potomac.

Part of Pharmala Biotech Holdings, Inc., Pharmala Biotech, Inc. is a Canadian biotechnology company that manufactures and sells MDMA and MDXX class molecules. The company is based in Toronto, Canada. The company was founded by Nicholas Kadysh. Nicholas Kadysh has been the CEO since incorporation.

Part of Pfizer Inc., Fluorinov Pharma, Inc. operates as a Canadian pharmaceutical company. The company is based in Toronto, Canada. The company was founded by Abdelmalik Slassi.